Abstract: A compound as shown in formula I. R1 is selected from the group consisting of —OH, —CH3, —CH2CH3, —OCH3, —OCH2CH3; R2 is selected from the group consisting of —H, —OH, —CH3, —CH2CH3, —CH2CH2CH3, —OCH3, —OCH2CH2CH3; R3 is selected from the group consisting of —F, —Cl, —Br, —I, —CF3; R4 is selected from the group consisting of —H, —F, —Cl, —Br, —I, —CF3; and R5 is selected from the group consisting of —H, —CH3, —CH2CH3.

Abstract: Provided an electrophotographic member having an excellent electroconductivity and being capable of forming a high quality electrophotographic image even in long-term use. The electrophotographic member comprises an electroconductive substrate and an electroconductive layer on the substrate, the electroconductive layer containing a matrix polymer, and a specific imidazolium salt.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The present invention relates to fluorescent dyes. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. In one aspect, the invention provides a compound having a maximal fluorescence excitation wavelength, wherein the compound has a structure of Formula II: F—Y=???Formula II and wherein Z— is a counterion, Y is a bridge unit permitting electron delocalization between F and ?, and F is a moiety having the structure: The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.

Abstract: Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula I are presented: wherein Q is a portion of a polymethine bridge: Also included are bioconjugates of the compounds of Formula I, methods of labeling biomolecules with the compounds, and methods of imaging.

Abstract: Methods of producing OLED materials containing fluorene ring systems in which two alkyl substituents at the 9-position of fluorene ring are alkyl substituted through key intermediates generically represented by the formula: where X represents a substituent that increases the acidity of the hydrogen atoms on the adjoining methylene group (which is immediately adjacent the fluorene ring systems 9-position).

Abstract: The invention relates to formulations comprising ionic organic compounds for use in electron transport layers or electron collecting layers of organic electronic (OE) devices, more specifically in organic photovoltaic (OPV) devices, to electron transport layers comprising or being made through the use of such formulations, and to OE and OPV devices comprising such formulations or electron transport layers.

Abstract: The invention relates to a family of dyes which fluoresce in the UV-VIS, far red and near infrared wavelengths of the spectrum and possess asymmetric lipophilic alkyl chains. The dyes of the invention are soluble in commercially available membrane staining dyes, are useful as probes for rapidly staining lipophilic structures such as membranes in cells or isolated from cells, and are well-retained therein. Methods of utilizing the dyes to detect stained cells both in vivo and in vitro are also disclosed.

Abstract: Disclosed are phenyl-oxazolyl derivatives having a general formula (I), a preparation method thereof, and an application of the phenyl-oxazolyl derivatives as an inosine monophosphate dehydrogenase (IMPDH) inhibitor.

Abstract: Disclosed is a process for preparing a polyester or copolymer containing ester functionalities. The process can comprise: providing an optionally substituted lactone having a ring size of from 6 to 40 carbon atoms; and subjecting said lactone to metal mediated ring-opening polymerization using as catalyst a compound according to general formula (I): wherein M can be Al, Cr, Mn and Co; X and X? are independently a heteroatom; Y and Y? can be, independently, selected from O, N, S, P, C, Si, and B; Z can be selected from hydrogen, borohydrides, aluminum hydrides, carbyls, silyls, hydroxide, alkoxides, aryloxides, carboxylates, carbonates, carbamates, amidos, thiolates, phosphides, and halides; L1 and L2 can be independently an organic ligand linking X and Y together and linking X? and Y? together, respectively; and L3 is an optional organic ligand linking Y and Y? together.

Abstract: Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula.

Abstract: The present invention relates to a novel coumarin derivative, to a method for preparing the same, and a multi-fluorescent substance that includes a plurality of the coumarin derivatives and is able to emit light using an LED light source. A novel coumarin derivative multi-fluorescent substance according to the present invention has an optimal emission wavelength band of 512 nm to 590 nm and thereby is effective in improving a signal intensity and stability since light emission using an LED light source is possible. In addition, higher fluorescence reactivity is exhibited compared to coumarin fluorescent substances known in the related arts since one molecule has a plurality of fluorescent substances, and the problem of the coumarin fluorescent substance possibly binding to a binding site of the antigen of the antibody is solved since fluorescence detection is possible even when a minimum number of fluorescent substance molecules bind to an antibody.

Abstract: A photoelectric conversion device capable of improving conversion efficiency is provided. The photoelectric conversion device includes a work electrode, an opposed electrode, and an electrolyte-containing layer. In the work electrode, a metal oxide semiconductor layer supporting a dye is provided. The dye contains a cyanine compound that has a methine chain, an indolenine skeleton bonded with both ends of the methine chain, and anchor groups introduced to a nitrogen atom included in the indolenine skeleton. Electron injection efficiency to the metal oxide semiconductor layer is improved, and the dye is hardly exfoliated from the metal oxide semiconductor layer.

Abstract: This invention is directed to a polyamic acid represented by the following formula (I), and an electrode having an active layer made from the polyamic acid of formula (I).

Abstract: The present invention pertains to a compound represented by a formula (I) and a method for producing thereof (in the formula, Ax is an organic group having 2 to 30 carbon atoms that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring, Ay is a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, a cycloalkyl group, an alkenyl group having 2 to 18 carbon atoms, an organic group having 2 to 30 carbon atoms that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring, or the like. Ax and Ay optionally bond to each other to form a ring, and Q is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like.).

Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.

Abstract: The present invention relates to a trimethine cyanine represented by the formula (1): wherein all symbols are defined as in the specification.

Abstract: The present invention relates to a polymerizable compound represented by a formula (I). The present invention provides a polymerizable compound, a polymerizable composition, a polymer, and an optically anisotropic article that are capable of obtaining an optical film having a low melting point, having excellent solubility, capable of being manufactured at low cost, and capable of uniform polarized light conversion across a broad wavelength region. [In formula: Y1 to Y6 are independently a chemical single bond, —O—, —O—C(?O)—, —C(?O)—O— etc.; G1 and G2 are independently a divalent C1-C20 aliphatic group etc.; Z1 and Z2 are independently C2-C10 alkenyl group that is substituted with a halogen atom etc.; Ax is a C2-C30 organic group that includes at least one aromatic ring selected from a group consisting of an aromatic hydrocarbon ring and an aromatic hetero ring; Ay is a hydrogen atom, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C3-C12 cycloalkyl group etc.; A1 is a trivalent aromatic group etc.

Abstract: Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer.

Abstract: This disclosure relates to compounds for use in light-emitting devices are described herein. These compounds may include a biphenyl that includes four substituents, such as benzoxazolyl, benzothiazolyl, or benzimidazolyl substituents, such as a compound represented by Formula 1. These compounds can incorporated into a nanostructure material or a plurality of nanostructures, which can be useful for light-scattering or light-extraction, for example, to increase the efficiency of light-emitting devices.

Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified to provide beneficial properties.

Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.

Abstract: This invention is directed to a polyamic acid represented by the following formula (I), and an electrode having an active layer made from the polyamic acid of formula (I).

Abstract: Cyanine dye compounds having a substituted methine moiety that are nucleic acid stains, particularly for fluorescent staining of RNA, including compounds having the formula where R1 is a C1-C6 alkyl, sulfoalkyl, carboxyalkyl or C1-C6 alkoxy; each R2 is independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, fused benzo, trifluoromethyl, amino, sulfo, carboxy and halogen, that is optionally further substituted; at least one of R3, R4, and R5 is an alkyl, aryl, heteroaryl, cyclic, or heterocyclic moiety that is optionally substituted by alkyl, amino, aminoalkyl, carboxy, nitro, or halogen; and the remaining R3, R4 or R5 are hydrogen; X is S, O, or Se; and D is a substituted or unsubstituted pyridinium, quinolinium or benzazolium moiety.

Abstract: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Abstract: Radiolabeled compounds useful as diagnostic imaging agents of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins, nucleic acids and cellular organelles. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified to provide beneficial properties.

Abstract: A molecular probe for use in the detection of myelin in a subject includes a compound having the general formula selected from the group consisting of: formula (I), and pharmaceutically acceptable salts thereof.

Abstract: A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hydrogen atom, a chlorine atom, or a fluorine atom provided that Y1 and Y2 do not represent hydrogen atoms at the same time; and X represents a counter anion. A pharmaceutical composition for treating leishmaniasis including the rhodacyanine derivative and a pharmaceutically acceptable carrier.

Abstract: Disclosed are nitro-substituted squaraine reporter dyes and methods using such dyes for detecting nitroreductase enzyme activity and nitroreductase gene expression in cellular assays.

Abstract: Cosmetic or dermatological preparations having an effective content of one or more thiazoles of the general formula

Abstract: An organic photoelectric conversion material for use in an organic thin-film photoelectric conversion device, containing a compound represented by formula 1; and an organic thin-film photoelectric conversion device having a photoelectric conversion layer which containing the organic photoelectric conversion material: wherein D represents an electron-donating aromatic substituent whose bonding site atom is a sp2 carbon atom; and a plurality of D may be the same or different from each other.

Abstract: A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hydrogen atom, a chlorine atom, or a fluorine atom provided that Y1 and Y2 do not represent hydrogen atoms at the same time; and X represents a counter anion. A pharmaceutical composition for treating leishmaniasis including the rhodacyanine derivative and a pharmaceutically acceptable carrier.

Abstract: The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect.

Abstract: An imide derivative represented by the following formula (A): wherein Ra and Rb are each a hydrogen atom, a halogen atom, a cyano group, an alkyl group, a fluoroalkyl group or an aryl group; at least one of Ra and Rb is a fluoroalkyl group; and Rc and Rd are each a substituted or unsubstituted benzyl group, an aryl group, a heterocycle, a fluoroalkyl group or an imide group.

Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

Abstract: A compound having Formula I wherein one of R1 and R2 is a group of the formula wherein R4 is selected from H and hydrocarbyl, R5 is a hydrocarbyl group and L is an optional linker group, or R1 and R2 together form a ring substituted with the group wherein R3 is H or a substituent, and wherein X is selected from S, O, NR6 and C(R7)(R8), wherein R6 is selected from H and hydrocarbyl groups, wherein each of R7 and R8 are independently selected from H and hydrocarbyl groups.

Abstract: The present invention has an object to provide a novel agent for anti-neurodegenerative diseases and solves the object by providing an agent for anti-neurodegenerative diseases containing, as an effective ingredient, the compound(s) represented by the following General formula 1: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; represents an integer of 0, 1 or 2; p represents an integer of 0 or 1, with the proviso that p is 1 when o is 0 or 2, and p is 0 when o is 1; R1 and R2 do not exist when o is 0, while, when p is 0, R3 does not exist and the binding between the carbon atom to which R2 binds and Z2 is a single bond; X1? represents an appropriate counter anion and q represents an integer of 1 or 2.

Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.

Abstract: A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.

Abstract: Disclosed are an organic composition including a compound represented by Chemical Formula 1, and an organic light emitting device including the composition. In Chemical Formula 1, A1, A2, A3, A4, B1, B2, B3 and B4 are independently selected from hydrogen, a C1 to C20 alkyl group, a C1 to C20 alkenyl group, an amino group, a C1 to C20 ether group, a C1 to C20 carboxyl group, a C1 to C20 ester group, a nitro group, a cyano group, a C3 to C30 aromatic group, and a halogen-containing group, provided that at least one of A1 to A4 and at least one of B1 to B4 are a substituted or unsubstituted aromatic group and form a fused ring structure by being bound to an adjacent substituent, M is a divalent or trivalent metal, X is oxygen (O) or sulfur (S), and y is 2 or 3.

Abstract: The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract: The present invention relates to a novel proton-conducting polymer membrane based on aromatic polyazoles which contain sulfonic acid groups and in which the sulfonic acid groups are covalently bound to the aromatic ring of the polymer and which can, owing to their excellent chemical and thermal properties, be used for a variety of purposes. Such materials are particularly useful for the production of polymer electrolyte membranes (PEMs) in PEM fuel cells.

Abstract: Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Abstract: The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof.

Abstract: A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.

Abstract: An aspect of the present invention relates to an optical information recording medium comprising a recording layer, wherein the recording layer comprises a cationic dye and a polynuclear azo metal complex dye comprising an azo dye and a metal ion, and a method of recording information comprising recording information on the recording layer comprised in the optical recording medium, and conducting the recording by irradiation of a laser beam having a wavelength of equal to or shorter than 440 nm onto the optical information recording medium. Another aspect of the present invention relates to a photo sensitizer.

Abstract: A compound represented by a Formula 1: wherein Ph1, Ar1, Ar2, Ar3 Bz1, Bz2, and Bz3 are described herein. Light-emitting devices containing the compound of Formula are also described herein.

Abstract: A compound having the general formula I or a conjugate thereof, wherein various groups are as defined in the specification. A composition includes: (i) a compound having the general formula I or a conjugate thereof; and (ii) at least one surfactant selected from cationic surfactants and nonionic surfactants. Also disclosed is a preparation method for the composition and a kit comprising the composition. Further disclosed is a method for identifying and differentiating erythroblasts, basophils and lymphocytes simultaneously using the composition according to the present disclosure.